Guggenheim has recently reduced Altimmune Inc (ALT) stock to Neutral rating, as announced on April 29, 2024, according to Finviz. Earlier, on January 24, 2024, Goldman had initiated the stock to Neutral, setting a price target of $13. Goldman also reduced Neutral rating with a price target of $6. Additionally, Goldman initiated Buy rating on December 1, 2022, with a target price of $20. Jefferies analysts, in their report published on December 29, 2021, also resumed Buy rating for Altimmune Inc’s stock. Analyst ratings are significant because they provide insights into stock performance expectations, influencing investor decisions and market sentiment.
Sponsored
Altimmune Inc (ALT) Stock Trading Recap
On Monday, Altimmune Inc (ALT) stock saw a decline, ending the day at $7.35 which represents a decrease of $-0.33 or -4.30% from the prior close of $7.68. The stock opened at $7.89 and touched a low of $6.92 during the day, reaching a high of $7.96. The volume of shares traded was 4.77 million exceeding the average volume of 2.14 million.
ALT Stock Performance and Moving Averages
In recent trading, Altimmune Inc (ALT) stock price has shown some volatility, fluctuating 8.25% over the last five trades and 16.67% over the past 30 trades. This represents a notable shift from earlier in the year. Over the last six months, the stock has risen by -0.27%, and it has gained 16.48% in the previous three months. Currently, ALT is trading at 5.24%, 7.63%, and -3.89% relative to its 20-Day, 50-Day, and 200-Day Simple Moving Averages, respectively.
As of the latest trading close, ALT, a Healthcare sector stock, is trading -50.47% below its 52-week high but remains 217.49% above its 52-week low. The Average True Range (ATR) (14 days) of 0.49 highlights the stock’s average volatility, providing insight into how much the price typically fluctuates. This measure is crucial for understanding potential price swings and assessing overall market risk.
Altimmune Inc’s Profitability and Valuation Ratios
Altimmune Inc’s profitability metrics reveal strong financial health. The company currently boasts an operating margin of -23785.57% and a profit margin of -24778.97%, with a gross margin of -0.27%. The profit margin, also known as the revenue ratio or gross profit ratio, measures how efficiently a company converts sales into net income; higher margins indicate greater profitability.
In terms of valuation, Altimmune Inc’s market capitalization stands at $537.77 million. Market cap represents the total value of all outstanding shares and is a key indicator of a company’s market value. Additionally, the Price-to-Sales Ratio is 1311.64, reflecting the market’s valuation of the company’s sales, while the Price-to-Book Ratio is 3.42, comparing the market value to the company’s book value.
Understanding Insider Trading
Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 0.83% of Altimmune Inc (ALT)’s shares, while financial institutions hold 59.21%.
Notable insider trades include Drutz David, Director at Altimmune Inc (ALT), who sold 16011 shares on Aug 19 ’24, at $6.9 each, totaling $0.11 million.
